Crizotinib is an antitumor drug, a first-generation targeted agent, which is for the treatment of patients with locally advanced or metastatic non-small cell lung cancer positive for mesenchymal lymphoma kinase. Crizotinib is a first-generation antitumor drug that inhibits the kinase of mesenchymal lymphoma, and was launched on January 22, 2013 in China. The recommended oral dose of crizotinib is 250mg/dose, 2 times/day. Due to the individual’s physical condition and tolerance to the adverse effects of the drug, the physician should be consulted promptly. The medication should be swallowed whole, not opened capsules, and can be taken with food. Serious side effects on the liver, kidneys, gastrointestinal tract, skin, vision, and fertility may occur after taking Crizotinib. Avoid driving if you experience blurred vision, dizziness, or fatigue after taking the medication. If you experience adverse reactions while taking the medication, talk to your doctor.